Earlier, Ferguson Pharmaceutical applied to the Hong Kong Department of Health for registration of traditional Chinese patent medicines and simple preparations - Shuanghuanglian Oral Liquid. On September 20, Fossen Shuanghuanglian Oral Liquid successfully passed the registration approval of the Traditional Chinese Medicine Division of the Hong Kong Chinese Medicine Regulatory Commission, and obtained the traditional Chinese patent medicines and simple preparations Registration Certificate in Hong Kong, with the registration number of HKC-18414.

According to relevant regulations of the Hong Kong Department of Health, Fosun Shuanghuanglian Oral Liquid can now be legally sold in Hong Kong. This marks a solid step towards the international market for Fosun Shuanghuanglian Oral Liquid, which has a positive impact on the company's product expansion in the international market.

▲ Please follow the drug instructions

Or purchase and use under the guidance of a pharmacist

Fushen Shuanghuanglian Oral Liquid is a leading product of Fushen Pharmaceutical's traditional Chinese medicine, which has entered the national essential drug catalog and the national medical insurance catalog (Class A). It is composed of honeysuckle, scutellaria baicalensis, and forsythia suspensa, and has the advantages of reducing fever without recurrence and quickly eliminating cough and sore throat; It also has antibacterial and antiviral effects and is a common medicine for families with wind and cold. In addition, in clinical practice, in addition to treating wind fever and common cold, Fosen Shuanghuanglian Oral Liquid is also included in guidelines and recommended medication plans for the prevention and treatment of diseases such as influenza, community-acquired pneumonia, Ebola hemorrhagic fever, Middle East respiratory syndrome, chickenpox in children, and acute upper respiratory tract infections in adults/children.

▲ Please follow the drug instructions

Or purchase and use under the guidance of a pharmacist

In the process of registration with the Hong Kong Department of Health, Fossen Shuanghuanglian Oral Liquid successfully passed the registration of traditional Chinese patent medicines and simple preparations in Hong Kong by submitting general information, safety information, effectiveness information and quality information. In order to control the quality of traditional Chinese medicine from the source, Fosun has established a 30000 acre high standard honeysuckle planting demonstration base. Through the integration and innovation of authentic medicinal material production technology, the uniformity and safety of the quality of honeysuckle have been effectively controlled, making the quality standards of honeysuckle in Fosun Shuanghuanglian oral liquid far exceed national standards. Since its launch, Fosun Shuanghuanglian Oral Liquid has been highly trusted by consumers due to its excellent efficacy and safety, and has been ranked among the top three similar products in China for many consecutive years. Nowadays, Fosun Shuanghuanglian Oral Liquid has entered thousands of households and is exported to countries such as Brazil and Mozambique. It is a "national qualified product with reliable quality standards".

As a modern comprehensive pharmaceutical enterprise that integrates the cultivation, research and development, production, and sales of medicinal materials, Fosun Pharmaceutical has always adhered to the corporate philosophy of "people-oriented, quality oriented". The company has continuously increased research investment and actively carried out technological innovation, forming a health industry group covering multiple fields such as traditional Chinese medicine, chemical medicine, and biopharmaceuticals. As a global financial center and an important market for traditional Chinese medicine, Hong Kong has a high international recognition of the traditional Chinese medicine industry. The successful registration of Fosun Shuanghuanglian Oral Liquid has helped to enhance the reputation and influence of Fosun Pharmaceutical in the international traditional Chinese medicine market.

In the future, Foxconn Pharmaceutical will take advantage of this successful registration to strengthen cooperation with domestic and foreign partners based in Hong Kong